Evidence map›Paper›PMID 26242312›Full record

ArticleBMC microbiology2015

Development of a heptaplex PCR assay for identification of Staphylococcus aureus and CoNS with simultaneous detection of virulence and antibiotic resistance genes.

Charles Emeka Okolie, Karl G Wooldridge, David P J Turner, Alan Cockayne, Richard James

Abstract read
In one paragraph

Article in BMC microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Preparation of IgY Oriented Conjugated FeFrontiers in public health · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charles Emeka OkolieCentre for Healthcare Associated Infections, Centre for Biomolecular Sciences Building, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK. okolie.charles@lmu.edu.ng.
Karl G WooldridgeCentre for Healthcare Associated Infections, Centre for Biomolecular Sciences Building, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK. karl.wooldridge@nottingham.ac.uk.
David P J TurnerCentre for Healthcare Associated Infections, Centre for Biomolecular Sciences Building, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK. david.turner@nottingham.ac.uk.
Alan CockayneCentre for Healthcare Associated Infections, Centre for Biomolecular Sciences Building, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK. alan.cockayne@nottingham.ac.uk.
Richard JamesCentre for Healthcare Associated Infections, Centre for Biomolecular Sciences Building, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK. richard.james@nottingham.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStaphylococcal toxicity and antibiotic resistance (STAAR) have been menacing public health. Although vancomycin-resistant Staphylococcus aureus (VRSA) is currently not as widespread as methicillin-resistant S. aureus (MRSA), genome evolution of MRSA into VRSA, including strains engineered within the same patient under anti-staphylococcal therapy, may build up to future public health concern. To further complicate diagnosis, infection control and anti-microbial chemotherapy, non-sterile sites such as the nares and the skin could contain both S. aureus and coagulase-negative staphylococci (CoNS), either of which could harbour mecA the gene driving staphylococcal methicillin-resistance and required for MRSA-VRSA evolution.

resultsA new heptaplex PCR assay has been developed which simultaneously detects seven markers for: i) eubacteria (16S rRNA), ii) Staphylococcus genus (tuf), iii) Staphylococcus aureus (spa), iv) CoNS (cns), v) Panton-Valentine leukocidin (pvl), vi) methicillin resistance (mecA), and vii) vancomycin resistance (vanA). Following successful validation using 255 reference bacterial strains, applicability to analyse clinical samples was evaluated by direct amplification in spiked blood cultures (n = 89) which returned 100 % specificity, negative and positive predictive values. The new assay has LoD of 1.0x10(3) CFU/mL for the 16S rRNA marker and 1.0x10(4) CFU/mL for six other markers and completes cycling in less than one hour.

conclusionThe speed, sensitivity (100 %), NPV (100 %) and PPV (100 %) suggest the new heptaplex PCR assay could be easily integrated into a routine diagnostic microbiology workflow. Detection of the cns marker allows for unique identification of CoNS in mono-microbial and in poly-microbial samples containing mixtures of CoNS and S. aureus without recourse to the conventional elimination approach which is ambiguous. In addition to the SA-CoNS differential diagnostic essence of the new assay, inclusion of vanA primers will allow microbiology laboratories to stay ahead of the emerging MRSA-VRSA evolution. To the best of our knowledge, the new heptaplex PCR assay is the most multiplexed among similar PCR-based assays for simultaneous detection of STAAR.

Indexed as

Drug Resistance, BacterialGenes, BacterialBacterial ProteinsHumansMultiplex Polymerase Chain ReactionPredictive Value of TestsRNA, Ribosomal, 16SSensitivity and SpecificityStaphylococcal InfectionsStaphylococcusTime FactorsVirulence FactorsBacterial ProteinsRNA, Ribosomal, 16SVirulence Factors

Identifiers

PMID26242312
PMCPMC4525735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.